January 26th Lunch & Learn Event on Sjogren’s Syndrome PDF Print E-mail
Thursday, 07 January 2010 12:16
For those of you in the state of Texas, Northwest Rheumatology, a division of Northwest Diagnostic Clinic, will host a free Lunch & Learn event on Sjogren’s Sydrome: The Forgotten Disease on Tuesday, Jan. 26, from 11:45 a.m. – 1 p.m. at the South Montgomery County Woodlands Chamber of Commerce Board Room.

Dr. Tamar Brionez of Northwest Rheumatology will speak on the definition, symptoms and therapeutics of Sjogren’s Syndrome, a disease often undiagnosed or misdiagnosed due to symptoms that mimic other medical conditions. This Lunch & Learn is the second in a quarterly series that will address a variety of health topics.

“This is a great topic to discuss,” said Dr. Brionez. “The lunch will be very informative and I look forward to addressing the questions and concerns commonly associated with Sjogren’s Syndrome. I am excited to be the next speaker in this series.”

The event is free and open to the public. Reservations are required and must be made by Friday, Jan. 22.

With four physicians on staff, Northwest Rheumatology specializes in the treatment of Rheumatoid Arthritis, Scleroderma, Sjogren’s Syndrome, Psoriatic Arthritis, Lupus and other autoimmune diseases, as well as Osteoporosis and Osteoarthritis. With offices in The Woodlands and Houston, the clinic offers several areas of expertise including family practice, internal medicine and rheumatology, as well as on-site ancillary services such as CT, MRI, nuclear medicine, ultrasound, bone density testing, infusion and laboratory services.

For more information, do click here.
 
More articles :

» Blocking TGFβ via Inhibition of the αvβ6 Integrin: A Possible Therapy for Systemic Sclerosis Interstitial Lung Disease

Tamiko R. Katsumoto, Shelia M. Violette, and Dean SheppardReceived 27 May 2011; Accepted 15 August 2011Interstitial lung disease (ILD) is a commonly encountered complication of systemic sclerosis (SSc) and accounts for a significant proportion of...

» Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?

Eric Hachulla, MD, PhD; David Launay, MD, PhD; Luc Mouthon, MD, PhD; Olivier Sitbon, MD, PhD; Alice Berezne, MD; Loïc Guillevin, MD; Pierre-Yves Hatron, MD; Ge´rald Simonneau, MD; Pierre Clerson, MD; and Marc Humbert, MD, PhD;Pulmonary arterial...

» Actelion Announces FDA Approval of Brand Name, Veletri, for Pulmonary Arterial Hypertension

US, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for...

» Millions Around World To Observe Rare Disease Day

Millions Around World To Observe Rare Disease DayThe Relief Foundation will be joining the National Organization for Rare Disorders (NORD) and others around the world in observing World Rare Disease Day on February 28, 2011.  On this day,...

» Prevention Of Vascular Damage In Scleroderma With Angiotensin-converting Enzyme (ACE) Inhibition

Great strides have been made in identifying and managing the organ-based complications of  systemic sclerosis (SSc). There is no room for the nihilism towards treating this disease that used to be so prevalent. However, there is still...

» Lidocaine for Systemic Sclerosis: A Double-blind Randomized Clinical Trial

Systemic sclerosis (scleroderma; SSc) is an orphan disease with the highest case-specific mortality of any connective-tissue disease. Excessive deposit in affected tissues is a key for the disease's pathogenesis and comprises most of the clinical...